RxDoctor Payments Data

Gonzalo Gonzalez, MD

Internal Medicine · Tampa, FLNPI 1053319699

Payments from drug & device makers

$1,021in general payments, 2019–2025

Across 20 payments — averaging $51.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$329
  • GSK$125
  • AstraZeneca$121
  • Apollo Endosurgery US Inc$118
  • Actelion Pharmaceuticals US, Inc.$85
  • Bayer$72
  • plus $170 from 8 others

What the payments were for

  • Food & beverage$93692%
  • Education$858%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,021 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$14,785
Medicare patients
67
Services billed
255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$48,451
JardianceEmpagliflozin36$35,573
TrulicityDulaglutide17$32,683
EliquisApixaban30$26,636
EntrestoSacubitril/Valsartan13$15,522
SymbicortBudesonide/Formoterol Fumarate31$12,457
Albuterol Sulfate HfaAlbuterol Sulfate89$2,867
Dexlansoprazole DrDexlansoprazole12$2,555
Atorvastatin Calcium259$2,406
Potassium Chloride44$2,389
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,089
Gabapentin121$1,749
Mirtazapine64$1,613
Alcohol Prep PadsAlcohol Antiseptic Pads22$1,571
Levothyroxine Sodium150$1,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$23$48,45132 claims
Boehringer IngelheimJardiance$16$35,57336 claims
Lilly USA, LLCTrulicity$43$32,68317 claims
PfizerEliquis$16$26,63630 claims
AstraZenecaSymbicort$121$12,45731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →